Endo Launches New Living Our Values Program to Recognize Outstanding Team Members

DUBLIN, March 3, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today honored select team members from across the world who exemplify Endo's Values as part of its inaugural Living Our Values Award program.  

"At Endo, we are motivated by a strong sense of purpose. We believe our Values – Collaboration, Innovation, Integrity & Quality, Drive and Empathy – are more than words on a page, and that how we work is as important as what we achieve," said Blaise Coleman, President and CEO of Endo. "I'm extremely proud to introduce the Living Our Values Award and look forward to recognizing, rewarding and celebrating those who inspire us by their example and help us deliver on our vision to help those we serve live their best life."

The first Living Our Values Award program provided winners with a monetary award as well as a celebration during which their contributions were honored by the Company's Senior Executive Leadership Team. Each recipient also received a special commemorative trophy to mark their accomplishment, and their names will be included in a permanent Living Our Values display at the Company's corporate office as well as on the corporate website. 

Winners were nominated by their peers, managers and business leaders and were selected for demonstrating excellence in living Endo's Values, Mission and Vision every day, as well as making a significant impact on advancing the Company's strategic priorities.

About Endo
Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Mr. Coleman. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this press release reflect Endo's current expectations of future events based on existing trends and information and represent Endo's judgment only as of the date of this press release. Actual results may differ materially and adversely from current expectations based on a number of factors affecting Endo's businesses including, among other things, the outcome of our strategic review, contingency planning and any potential restructuring; the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; and the impact of competition including loss of exclusivity and generic competition. The reader is cautioned not to rely on any forward-looking statements and Endo expressly disclaims any intent or obligation to update any forward-looking statements except as required by law. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo, as well as Endo's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading "Risk Factors" in Endo's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission.

SOURCE Endo International plc

Endo International plc: Media: Heather Zoumas-Lubeski, [phone], [email protected], or Investors: Pravesh Khandelwal, [email protected]